Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of BotensilimabWith or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
Fakih, et al.
Filter by
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Journal of Clinical Oncology
Jan 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of BotensilimabWith or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
Fakih, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
A Phase I Trial of Folinic Acid, Fluorouracil, Oxaliplatin, Bevacizumab, Botensilimab, Balstilimab (FOLFOX-3B) in Microsatellite Stable Metastatic Colorectal Cancer
Fakih, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable, locally
advanced pMMR or dMMR colon cancer: results from the UNICORN trial by GONO
Ghelardi et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Neoadjuvant Botensilimab (BOT) Plus Balstilimab (BAL) in Resectable Mismatch Repair Proficient (pMMR) and Deficient (dMMR) Colorectal Cancer (CRC)
Hissong et al.
AGENT-797 (Allogeneic iNKT Cell Therapy), Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
TPS 515: A phase II study of agenT-797 (invariant natural killer T cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
Cytryn et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Cancer Discovery
Dec 2, 2024
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
AGEN1721
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2024
AGEN1721, a First-in-Class FC-Enhanced Bifunctional Antibody Targeting FAP and TGFB, Remodels the Tumor Microenvironment to Overcome Cancer-Associated Fibroblast-Mediated Immune Suppression
Iyer et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 8
- Nov 10, 2024
Preclinical Dose-Pharmacokinetic-Efficacy Modeling of Botensilimab Using a Mouse Surrogate of the Fc-Enhanced Anti-CTLA-4 Antibody
Savitsky, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2024
Fc-Enhanced Anti-CTLA-4 Antibody, Botensilimab, Enhances the Efficacy of Multiple Therapeutic Modalities in Immunotherapy-Refractory Tumor Models
Levey, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Nature Medicine
Sep 30, 2024
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology
Sep 13
- Sep 17, 2024
Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study
Wilky, et al.